Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib plus enzalutamide versus placebo plus enzalutamide in DDR-mutated metastatic castration-sensitive prostate cancer
NL-OMON60831Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Talazoparib + enzalutamide with Placebo + enzalutamide (2 arms). Primary endpoint: Radiographic progression-free survival. Started Feb 2022; status: active, not recruiting.
02
Drugs
talazoparibenzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON60831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60831.